Juniper Publishers-Journal of Diabetes Obesity Journal

  In 2025, the academic publishing landscape continues to evolve rapidly. With the rise of open-access publishing, researchers now have more opportunities than ever to share their findings globally. Among the publishers frequently discussed in this space is Juniper Publishers — often associated with accessibility, faster publication timelines, and international reach. But an important question many researchers ask is: Is Juniper Publishers legitimate in 2025? This transparent review examines what the publisher offers, what researchers typically look for, and whether it may align with your academic publishing goals. Juniper Publishers in 2025: An Overview As of 2025, Juniper Publishers remains an active open-access academic publisher serving researchers across scientific, medical, and interdisciplinary fields. Many authors choose Juniper for several practical reasons, including: Faster editorial and peer-review timelines A user-friendly manuscript subm...

Juniper Publishers plays a pivotal role in advancing open science by fostering accessibility, transparency, and collaboration within the global research community. Their commitment to open science is reflected through various initiatives that remove barriers to knowledge and promote the dissemination of research findings.   1. Open Access Journals One of the primary ways Juniper Publishers promotes open science is through its open-access publishing model. By offering free and unrestricted access to scientific research articles, they ensure that anyone, regardless of their location or financial resources, can access valuable scientific knowledge. This open-access approach dismantles the paywall barriers typically associated with traditional publishing, thus making research accessible to a wider audience, including researchers, students, policymakers, and the general public. 2. Encouraging Collaboration and Networking Juniper Publishers fosters an environment that encourages coll...

  CURRENT RESEARCH IN DIABETES & OBESITY JOURNAL JUNIPER PUBLISHERS Authored by Leila Ben Amor Abstract Objective: To describe clinical factors associated with SGA-induced weight gain induced by long-term second generation antipsychotic (SGA) treatment in children and adolescents. Methods: A 24-month retrospective study conducted between November 2005 and June 2013. 147 antipsychotic-naive patients were selected [mean age 12.8; (95% CI 9.8 to 15.9)] and treated with an SGA (risperidone, olanzapine, quetiapine and aripiprazole) for up to 24 months. Weight and height were measured and BMI (body mass index) z-scores were calculated at baseline, 1, 3, 6, 12 and 24 months. Linear mixed-model analysis was used to compare weight, BMI and BMI z-score changes of the SGA treatment with the repeated factor being the time relative to baseline at 1, 3, 6, 12 and 24 months. Results: After 24 months of SGA treatment, mean weight increased significantly by 12.8 kg (95% C...